{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:37:53Z","timestamp":1780504673044,"version":"3.54.1"},"reference-count":50,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001127","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001127","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2486839","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T11:19:56Z","timestamp":1743419996000},"page":"596-605","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States"],"prefix":"10.1080","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3168-2521","authenticated-orcid":false,"given":"Zahra","family":"Mahmoudjafari","sequence":"first","affiliation":[{"name":"The University of Kansas Health System","place":["Kansas City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[{"name":"Genentech, Inc","place":["South San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bercaw","sequence":"additional","affiliation":[{"name":"Medicus Economics, LLC","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Paris\u00e9","sequence":"additional","affiliation":[{"name":"Medicus Economics, LLC","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Bognar","sequence":"additional","affiliation":[{"name":"Medicus Economics, LLC","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Tien","family":"Wang","sequence":"additional","affiliation":[{"name":"Medicus Economics, LLC","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Masaquel","sequence":"additional","affiliation":[{"name":"Genentech, Inc","place":["South San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60605-9"},{"key":"e_1_3_6_3_1","unstructured":"American Cancer Society. Cancer facts & figures 2023. Atlanta (GA); 2023 [cited 2023 Sep 21]. Available from: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2023\/2023-cancer-facts-and-figures.pdf"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010005"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/02841860500531682"},{"key":"e_1_3_6_6_1","unstructured":"National Cancer Institute. Cancer Stat Facts: NHL \u2013 diffuse large B-cell lymphoma (DLBCL). Bethesda (MD); 2023 [cited 2023 Sep 21]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.5866"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.21037\/aol-22-3"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.9593"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.9416"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14813"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_3_6_16_1","unstructured":"Kite Pharma Inc. YESCARTA prescribing information. Santa Monica (CA): Kite Pharma Inc.; 2022 [cited 2023 Mar 14]. Available from: https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/oncology\/yescarta\/yescarta-pi.pdf"},{"key":"e_1_3_6_17_1","unstructured":"Bristol Myers Squibb. BREYANZI prescribing information. Bothell (WA): Juno Therapeutics Inc. a Bristol-Myers Squibb Company; 2022 [cited 2023 Mar 14]. Available from: https:\/\/packageinserts.bms.com\/pi\/pi_breyanzi.pdf"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018730"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"e_1_3_6_21_1","unstructured":"Novartis Pharmaceuticals Corporation. KYMRIAH prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2022 [cited 2023 Mar 14]. Available from: https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/kymriah.pdf"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2021.88737"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-022-00428-w"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7"},{"key":"e_1_3_6_26_1","unstructured":"Genmab US Inc. EPKINLY prescribing information. Plainsboro (NJ): Genmab US Inc.; 2023 [cited 2023 Mar 9]. Available from: https:\/\/www.genmab-pi.com\/prescribing-information\/epkinly-pi.pdf"},{"key":"e_1_3_6_27_1","unstructured":"Genentech Inc. COLUMVI prescribing information. South San Francisco (CA): Genentech USA Inc.; 2023 [cited 2023 Jun 16]. Available from: https:\/\/www.gene.com\/download\/pdf\/columvi_prescribing.pdf"},{"key":"e_1_3_6_28_1","unstructured":"ADC Therapeutics. ZYNLONTA prescribing information. Murray Hill (NJ): ADC Therapeutics America; 2022 [cited 2023 Mar 14]. Available from: https:\/\/www.adctherapeutics.com\/wp-content\/uploads\/2022\/10\/ZYLONTA-PI_October-2022_LOCKED.pdf"},{"key":"e_1_3_6_29_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines\u00ae) for B-cell lymphomas V.1.2024. \u00a9 National Comprehensive Cancer Network Inc.; 2024. All rights reserved."},{"key":"e_1_3_6_30_1","unstructured":"Genentech Inc. POLIVY prescribing information. South San Francisco (CA): Genentech Inc.; 2020 [cited 2023 Mar 14]. Available from: https:\/\/www.gene.com\/download\/pdf\/polivy_prescribing.pdf"},{"key":"e_1_3_6_31_1","unstructured":"MORPHOSYS US INC. MONJUVI prescribing information. Boston (MA): MORPHOSYS US Inc.; 2021 [cited 2023 Mar 14]. Available from: https:\/\/www.monjuvi.com\/pi\/monjuvi-pi.pdf"},{"key":"e_1_3_6_32_1","unstructured":"Bristol Myers Squibb. REVLIMID prescribing information. Summit (NJ): Celgene Corporation; 2021; 2022 [cited 2023 Mar 14]. Available from: https:\/\/packageinserts.bms.com\/pi\/pi_revlimid.pdf"},{"key":"e_1_3_6_33_1","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas. Silver Spring (MD); 2023 [updated 2023 Jun 15; cited 2023 Jun 15]. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-glofitamab-gxbm-selected-relapsed-or-refractory-large-b-cell"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"e_1_3_6_35_1","unstructured":"United States Bureau of Labor Statistics. CPI for all urban consumers (CPI-U). US city average medical care (CUUR0000SAM). Washington (DC); 2023 [cited 2023 Mar 15]. Available from: https:\/\/data.bls.gov\/cgi-bin\/surveymost?cu"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.2291"},{"key":"e_1_3_6_37_1","unstructured":"Keisler-Starkey K Bunch LN. Health insurance coverage in the United States: 2020. Washington (DC): US Census Bureau; 2021 [cited 2023 Mar 22]. Available from: https:\/\/www.census.gov\/content\/dam\/Census\/library\/publications\/2021\/demo\/p60-274.pdf"},{"key":"e_1_3_6_38_1","unstructured":"National Cancer Institute. SEER Cancer Statistics Review (CSR) 1975-2017. Section 19. Non-Hodgkin lymphoma. Table 19.26: all lymphoid neoplasms with detailed non-Hodgkin lymphoma subtypes. Bethesda (MD); 2022 [cited 2020 Oct 28]. Available from: https:\/\/seer.cancer.gov\/archive\/csr\/1975_2017\/results_merged\/sect_19_nhl.pdf"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1975188"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-5-13"},{"key":"e_1_3_6_41_1","unstructured":"AnalySource\u00ae. Reprinted with permission by First Databank Inc. All rights reserved; 2023."},{"key":"e_1_3_6_42_1","unstructured":"Centers for Medicare & Medicaid Services. Medicare part B drug and biological average sales price quarterly payment files. Baltimore (MD); 2023 Jan [updated 2023 Mar 22; cited 2023 Mar 22]. Available from: https:\/\/www.cms.gov\/medicare\/medicare-part-b-drug-average-sales-price\/2023-asp-drug-pricing-files"},{"key":"e_1_3_6_43_1","unstructured":"Centers for Medicare & Medicaid Services. Addendum A and addendum B updates. Baltimore (MD); 2023 [updated 2023 Mar 22]. Available from: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/HospitalOutpatientPPS\/Addendum-A-and-Addendum-B-Updates"},{"key":"e_1_3_6_44_1","unstructured":"Referenced with permission from the NCCN Chemotherapy Order Templates (NCCN Templates\u00ae) \u00a9 National Comprehensive Cancer Network Inc.; 2024. All rights reserved."},{"key":"e_1_3_6_45_1","unstructured":"Centers for Medicare & Medicaid Services. CY 2023 physician fee schedule. Baltimore (MD); 2023 [updated 2023 Mar 22; cited 2023 Mar 22]. Available from: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search\/overview"},{"key":"e_1_3_6_46_1","unstructured":"Centers for Medicare & Medicaid Services. CY 2023 Q1 release: clinical diagnostic laboratory fee schedule (CDLFS). Baltimore (MD); 2023 [updated 2023 Mar 22; cited 2023 Mar 22]. Available from: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/ClinicalLabFeeSched\/Clinical-Laboratory-Fee-Schedule-Files"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004567"},{"key":"e_1_3_6_49_1","unstructured":"Agency for Healthcare Research and Quality. Healthcare Cost and Utlization Project (HCUP). Release of the 2017 National Inpatient Sample (NIS) (December 2019). North Bethesda (MD); 2019 [cited 2023 Mar 22]. Available and accessed in the United States from: https:\/\/hcup-us.ahrq.gov\/news\/announcements\/nis2017.jsp"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.10.009"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02079"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2486839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:05:22Z","timestamp":1776679522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2486839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2486839"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2486839","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}